

Alexa Fluor[®] 488 anti-mouse CD11c Antibody

Catalog# / Size	117313 / 25 µg 117311 / 100 µg
Clone	N418
Regulatory Status	RUO
Other Names	αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype	Armenian Hamster IgG
Description	CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	Mouse spleen dendritic cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Preparation	The antibody was purified by affinity chromatography and conjugated with Alexa Fluor [®] 488 under optimal conditions.
Concentration	0.5 mg/mL
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 ⁶ cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for other applications.

* Alexa Fluor[®] 488 has a maximum emission of 519 nm when it is excited at 488 nm.

Alexa Fluor[®] and Pacific Blue™ are trademarks of Life Technologies Corporation.

[View full statement regarding label licenses](#)

Excitation Laser	Blue Laser (488 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ³ , immunohistochemical staining of acetone-fixed frozen sections ³ , immunofluorescence microscopy ⁵ , ⁹ (Alexa Fluor [®] 488 conjugated N418 was used for IHC in frozen sections ¹⁰), and spatial biology (IBEX) ^{22,23} .

Application References

(PubMed link indicates BioLegend citation)

1. Granucci F, et al. 1997. *J. Immunol.* 159:1794.
2. Stokes RW, et al. 1998. *J. Immunol.* 160:5514.
3. Metlay JP, et al. 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, et al. 2006. *Cancer Research* 66:1169.
5. Chin RK, et al. 2006. *J. Immunol.* 177:290. (IF)
6. Cervantes-Barragan L, et al. 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, et al. 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)

8. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, *et al.* 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, *et al.* 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, *et al.* 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, *et al.* 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, *et al.* 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, *et al.* 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, *et al.* 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, *et al.* 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, *et al.* 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, *et al.* 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, *et al.* 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, *et al.* 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Chen G, *et al.* 2016. *J Immunol.* 196: 1810 - 1821. [PubMed](#)
2. Kawabe T, *et al.* 2020. *Nat Commun.* 2.795833333. [PubMed](#)
3. You Y, *et al.* 2009. *J Immunol.* 182:7343. [PubMed](#)
4. Platt DJ, *et al.* 2021. *Cell Reports.* 35(6):109113. [PubMed](#)
5. Hu HJ, *et al.* 2020. *Cell Death Dis.* 1.168055556. [PubMed](#)
6. Mogilenko DA, *et al.* 2020. *Immunity.* 54(1):99-115.e12. [PubMed](#)
7. Lino AC *et al.* 2018. *Immunity.* 49(1):120-133. [PubMed](#)
8. Ooi JD, *et al.* 2019. *Nat Commun.* 10:3392. [PubMed](#)
9. Mason HD, *et al.* 2021. *JCI Insight.* 6:e149229. [PubMed](#)
10. Coleby R, *et al.* 2021. *Clin Exp Rheumatol.* :39. [PubMed](#)
11. Zhang S, *et al.* 2021. *Cell.* 184(8):2151-2166.e16. [PubMed](#)
12. Hays C, *et al.* 2020. *eLife.* 8:e48772.. [PubMed](#)
13. De Vlaeminck Y, *et al.* 2020. *Cancers (Basel).* 12:. [PubMed](#)
14. Bangs DJ, *et al.* 2022. *Cell Rep.* 38:110266. [PubMed](#)
15. Liu W, *et al.* 2021. *Cell Mol Immunol.* 18:2660. [PubMed](#)
16. Khandelwal P, *et al.* 2013. *PLoS One.* 8:64193. [PubMed](#)
17. Jtte BB, *et al.* 2021. *iScience.* 24(8):102833. [PubMed](#)
18. Roland C, *et al.* 2009. *PLoS One.* 4:e7669. [PubMed](#)
19. Li S, *et al.* 2021. *Ann Transl Med.* 9:1644. [PubMed](#)
20. Yang H, *et al.* 2015. *Cancer Res.* 75: 3812-3822. [PubMed](#)
21. Mohan J, *et al.* 2013. *J Exp Med.* 210:2403. [PubMed](#)
22. Bhattacharjee A, *et al.* 2019. *Commun Biol.* 2:450. [PubMed](#)
23. Wan W, *et al.* 2013. *Cardiovasc Res.* 97:580. [PubMed](#)
24. Wei SC, *et al.* 2020. *Cancer Discov.* . [PubMed](#)
25. Maston LD, *et al.* 2017. *Am J Physiol Lung Cell Mol Physiol.* 312:L609. [PubMed](#)
26. Chen C, *et al.* 2019. *Cell Rep.* 29:4200. [PubMed](#)
27. Wang S, *et al.* 2018. *Biomaterials.* 187:28:00. [PubMed](#)
28. Roland C, *et al.* 2009. *Mol Cancer Ther.* 1.55625. [PubMed](#)
29. Jiang H, *et al.* 2016. *J Immunol.* 197: 2880 - 2890. [PubMed](#)
30. Xue N, *et al.* 2017. *Sci Rep.* 7:39011. [PubMed](#)
31. Dey S, *et al.* 2020. *J Immunother Cancer.* 8:. [PubMed](#)
32. Collins N, *et al.* 2016. *Nat Commun.* 7:11514. [PubMed](#)
33. Napp J, *et al.* 2019. *Theranostics.* 4.754861111. [PubMed](#)
34. Simula L *et al.* 2018. *Cell reports.* 25(11):3059-3073. [PubMed](#)
35. Hamaidi I, *et al.* 2020. *Cell Metabolism.* 32(3):420-436.e12. [PubMed](#)
36. Calderon B, *et al.* 2015. *J Exp Med.* 212: 1497-1512. [PubMed](#)
37. Liu P, *et al.* 2020. *Mol Cell.* 748:77. [PubMed](#)
38. Miyajima M, *et al.* 2017. *Nat Immunol.*.. 10.1038/ni.3867. [PubMed](#)
39. Rosato PC, *et al.* 2019. *Nat Commun.* 10:567. [PubMed](#)
40. Foster G, *et al.* 2015. *J Immunol.* 195: 5380 - 5392. [PubMed](#)
41. Yates J, *et al.* 2013. *J Immunol.* 191:1240. [PubMed](#)
42. Riedelberger M, *et al.* 2020. *Cell Host & Microbe.* 27(3):454-466. [PubMed](#)
43. Lee GR, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
44. Morrissey MA, *et al.* 2018. *Elife.* 7:e36688. [PubMed](#)

RRID

AB_492849 (BioLegend Cat. No. 117313)
 AB_389306 (BioLegend Cat. No. 117311)

Antigen Details

Structure	Integrin α -chain, associates with integrin β_2 (CD18), 150 kD
Distribution	Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells
Function	Cellular adhesion
Ligand/Receptor	iC3b, fibrinogen

Cell Type	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen Facts Book Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol.</i> 156:3780.
Gene ID	16411



Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

Product Data



C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and Alexa Fluor® 488 N418 (top) or Alexa Fluor® 488 Armenian hamster IgG isotype control (bottom)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587